The Company's full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.
Key Business Highlights
On January 30, 2026, the Company announced the appointment of Mr. Eyal Gabbai to its Board of Directors, bringing large-scale healthcare system and capital markets experience. Mr. Gabbai replaced Dr. Gadi Riesenfeld, who will continue to support the Company as a member of the Scientific Advisory Board.
On February 10, 2026, the Company announced positive results from an independent proteomic analysis conducted at the Technion - Israel Institute of Technology. The study evaluated multiple production batches of NurExone's exosomes and confirmed batch-to-batch consistency through a repeatable protein "fingerprint." By supporting the Company's Chemistry, Manufacturing and Controls ("CMC") readiness, a critical requirement for a potential investigational new drug application, these results advance the Company's manufacturing and regulatory roadmap.
On March 10, 2026, the Company completed a non-brokered private placement (the "March 2026 Private Placement") of units of the Company (each, a "March 2026 Unit") through the issuance of an aggregate of 1,295,222 March 2026 Units. Each March 2026 Unit was issued at a price of C$0.68 per March 2026 Unit generating aggregate gross proceeds of approximately US$642 thousand (C$881 thousand), with issuance costs of approximately US$9 thousand (C$12 thousand). Each March 2026 Unit was comprised of (i) one common share in the capital of the Company (each, a "Common Share") and (ii) one Common Share purchase warrant (each, a "March 2026 Warrant"). Each March 2026 Warrant entitles the holder thereof to purchase one Common Share at a price of C$0.85 per Common Share for a period of 36 months from the closing date, subject to acceleration. If the daily volume weighted average trading price of the Common Shares on the TSX Venture Exchange ("TSXV") for any period of 20 consecutive trading days equals or exceeds C$1.70, the Company may, upon providing written notice to the holders of the March 2026 Warrants (the "March 2026 Offering Acceleration Notice"), accelerate the expiry date of the March 2026 Warrants to the date that is 30 days following the date of the March 2026 Offering Acceleration Notice. If the March 2026 Warrants are not exercised by the accelerated expiry date, the March 2026 Warrants will expire and be of no further force or effect. All securities issued under the March 2026 Private Placement were issued subject to applicable statutory hold periods.
On March 26, 2026, the Company announced that its subsidiaries Exo-Top Inc. ("Exo-Top") and NurExone Biologic Ltd. entered into a sublicense agreement granting Exo-Top certain rights under the Company's existing technology license agreement with Technion Research and Development Foundation Ltd. and Ramot, Tel Aviv University's technology transfer company. The sublicense further establishes Exo-Top's role in NurExone's U.S. strategy and is intended to support future manufacturing, development, and commercialization activities for naïve exosomes in North America.
On March 27, 2026, the Company was awarded first place ...
